Valproate-Induced Non-Hepatic Hyperammonaemic Encephalopathy: A Rare Complication of Chronic Valproate Therapy

Amit Agrawal\textsuperscript{a,c}, Rashmi Agrawal\textsuperscript{b}

Abstract

Valproic acid can sometimes produce encephalopathy secondary to hyperammonemia without hepatic dysfunction, termed as valproate-induced hyperammonaemic encephalopathy (VHE). VHE is characterized by acute onset of impaired consciousness, lethargy, confusion, headache, vomiting, seizures and focal neurological deficits. Known risk factors include therapy with multiple antiepileptic drugs, presence of underlying inborn errors of metabolism, febrile states, and insufficient nutritional intake. We hereby, describe a case of VHE in a 10-year-old male child on long-term VPA therapy and no history of underlying liver disease. Encephalopathy reversed on withdrawal of VPA and L-carnitine therapy. We emphasize the need for early recognition, investigation, and treatment of this potentially life-threatening condition.

Keywords: Encephalopathy; Hyperammonemia; Valproic acid

Introduction

Valproic acid (VPA) is an anti-epileptic drug (AED) commonly used in children to treat generalized and partial epilepsy syndromes because of its broad spectrum of activity [1]. Although, valproate-induced hepatic encephalopathy is a well-recognized entity, it can sometimes produce encephalopathy without hepatic dysfunction, termed as valproate-induced hyperammonemic encephalopathy (VHE). VHE is characterized by acute onset of impaired consciousness, headache, vomiting, seizures, and focal neurological deficits or ataxia, with rapid recovery after discontinuation of VPA. Although, pathogenesis of VHE is not well understood, hyperammonemia has been implicated in causation of encephalopathy [2].

Most of the cases reported in literature developed encephalopathy early after initiation of VPA. However, our case illustrates that VHE can occur during chronic VPA therapy also. Therefore, in any patient on VPA therapy presenting with signs of encephalopathy, ammonia level should be checked and VPA should be discontinued. As in our case, encephalopathy reversed following withdrawal of VPA, which emphasizes the importance of early diagnosis and treatment.

Case Report

A 10-year-old male child brought with recurrent vomiting, headache, confusion and one episode of generalised convulsions followed by drowsiness. He was born at term with normal birth history and normal developmental milestones. He was a known case of idiopathic generalized epilepsy since 7 years of age. He was treated initially with phenytoin and switched over to sodium valproate (200 mg twice a day) since last one year. On examination, child was drowsy with normal vitals. His fundus examination was normal and pupils were symmetrical, normally reacting to light. There was no focal deficit, and no meningeal signs were there. The motor and sensory examination including deep tendon reflexes were normal.

Twenty-four hours after the episode of convulsion, child was given L-carnitine and serum ammonia level was estimated which was raised to 114 μmol/L (normal range 12 - 47 μmol/L). The levels of serum valproate were found to be within normal range (63 μg/mL, normal range 50 - 100 μg/mL).

As liver function tests were normal, and serum ammonia level was raised, the diagnosis of VHE was made. Subsequently, levels of ammonia were monitored daily, and the child was treated with L-carnitine and dietary modification. The levels of serum ammonia fell to normal within 48 hours following treatment. Thereafter, the patient was started on lamotrigine and discharged on follow-up.

Manuscript accepted for publication June 11, 2012

\textsuperscript{a}Department of Pediatrics, Gandhi Medical College & Kaml Nehru Hospital, Bhopal, India
\textsuperscript{b}Devnata Hospital, Bhopal, Devnata Hospital Anina Vihar Colony, Ayodhya Bypass Road, Bhopal - 462030, MP, India
\textsuperscript{c}Corresponding author: Amit Agrawal, 28, Ravidas Nagar, Near Nizamuddin Colony, Indrapuri, Bhopal, MP, India - 462021.
Email: agrawalramit@yahoo.co.in
doi:10.4021/ijcp33w
nia was raised, a diagnosis of valproate induced non-hepatic hyperammonemic encephalopathy was suspected. The valproate was immediately discontinued and replaced by levetiracetam along with L-carnitine supplementation. With these interventions, patient showed rapid recovery over next 4 days and became well oriented, alert and attentive. On repeat estimation, serum ammonia level declined to the normal level (26 μmol/L).

Discussion

The index case was a child on long-term valproate therapy, presented with clinical features of metabolic encephalopathy, hyperammonaemia and no signs of liver failure. His symptoms were relieved after discontinuation of VPA, with the normalization of serum ammonia level suggesting a clinical diagnosis of VHE. Although, valproate-induced hepatic dysfunction leading to encephalopathy is a known complication, VHE without liver disorder is relatively rare and serious side effect of valproate therapy and only a few case reports are available on occurrence of VHE following chronic use of VPA [3-4]. The typical presentation of VHE include acute onset of impaired consciousness, confusion and lethargy, which may progress to stupor and coma. Focal neurological symptoms and increased seizure frequency may be present [1]. In chronic therapy, onset can be insidious. Although, the incidence of VHE is unknown, mild asymptomatic elevations in serum ammonia have been described in 16% - 52% of patients receiving valproate therapy [5].

Other causes of hyperammonemia without hepatic dysfunction include inborn errors of metabolism (e.g. urea cycle enzyme defects, fatty acid oxidation defects), drugs (e.g. 5-FU, asparaginase, salicylate, halothane and enflurane), hematologic diseases like multiple myeloma and acute myeloblastic leukemia, hyperinsulinemia, hyperglycaemia, distal renal tubular acidosis, parenteral nutrition and Reye’s syndrome [6]. In our patient, we found urea cycle defects and other metabolic disorders very unlikely and we did not do an extensive metabolic workup in our patient, as there was no previous history of protein intolerance and no reported neonatal, adolescent, or adult deaths in the family. We decided to first withdraw VPA to assess the response as it is known to produce hyperammonemia and our approach was justified by the dramatic clinical improvement after drug withdrawal. We would have investigated the underlying metabolic disorders in case of less dramatic response. Serum valproate level was within normal limits, although there is little correlation between valproate level and clinical effects because of its variable absorption and short half-life [7]. It also correlates poorly with the occurrence of hyperammonemia [8-9].

Several mechanisms have been proposed to explain VPA-induced hyperammonaemic encephalopathy e.g. changes in dietary protein intake, increased production of ammonia in the kidney by VPA and inhibition of mitochondrial carbamoyl phosphate synthetase enzymes in the liver by active metabolites of VPA, which is necessary for ammonia elimination via urea cycle [4, 10]. Additionally, chronic valproate therapy increases the amount of VPA oxidation and production of active metabolites in the liver [11]. Also, chronic VPA therapy enhances urinary excretion of L-carnitine, resulting in depletion of blood carnitine stores leading to reduced capacity of ammonia metabolism [12].

Concomitant use of other AEDs like topiramate, carbamazepine and phenobarbitone may elevate the free biologically active fraction of valproate leading to hyperammonemia [5, 13]. Other risk factors for the development of VHE include young age, multiple neurological disabilities, and poor nutritional intake [14]. High cerebral levels of ammonia leads to an increase in glutamine level in the brain due to increased production and decreased excretion in the astrocytes, which in turn leads to astrocyte swelling and cerebral oedema [15]. Also, increase in activation of gamma-aminobutyric acid (GABA) by ammonia induces somnolence [5]. Treatment for VHE includes supportive care and withholding valproate. L-carnitine is frequently used to treat VHE [16-17]. Extremely high concentrations of ammonia may warrant dialysis [18].

Conclusion

VHE is a rare and serious side effect of valproic acid and it may be overlooked when the serum valproate level and liver function tests are within the normal ranges. Thus, we conclude that a high index of suspicion is required for an early recognition and treatment of this potentially life-threatening condition. In a patient taking VPA and presenting with encephalopathy or unexplained increase in seizure frequency, ammonia levels should be checked and valproic acid should be discontinued.

Authorship Contributions

RA: Patient management, acquisition of data, drafting the article, and literature review; AA: Concept, manuscript review, manuscript editing, revising the article critically for important intellectual content; AA will act as guarantor. Both the authors approved the final manuscript.

Conflict of Interested

None.

References

1. Coulter DL, Wu H, Allen RJ. Valproic acid therapy in
Valproate-Induced Hyperammonaemic Encephalopathy